In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

In patients with nonalcoholic fatty liver disease (NAFLD), a liver biopsy remains the only reliable way to differentiate simple steatosis from nonalcoholic steatohepatitis (NASH). Noninvasive methods are urgently needed. Increasing evidence suggests hepatocyte apoptosis is a key mediator of liver injury in NAFLD. The aim of this study was to quantify hepatocyte apoptosis in plasma from patients with NAFLD and correlate it with histological severity. Plasma was obtained from 44 consecutive patients with suspected NAFLD at the time of liver biopsy. Histology was assessed blindly. Caspase‐3–generated cytokeratin‐18 fragments were measured in situ via immunohistochemistry and in vivo using a novel enzyme‐linked immunosorbent assay. Plasma cytokeratin‐18 fragments were markedly increased in patients with NASH compared with patients with simple steatosis or normal biopsies (median [interquartile range]: 765.7 U/L [479.6–991.1], 202.4 U/L [160.4–258.2], 215.5 U/L [150.2–296.2], respectively; P < .001). Cytokeratin‐18 fragment levels independently predicted NASH (OR 1.95; 95% CI 1.18–3.22; P = .009 for every 50 U/L increase). A cutoff value of 395 U/L calculated using the receiver operating characteristic curve approach showed a specificity of 99.9%, a sensitivity of 85.7%, and positive and negative predictive values of 99.9% and 85.7%, respectively, for the diagnosis of NASH. In conclusion, these findings strongly suggest that determination of hepatocyte caspase activation in the blood is a strong and independent predictor of NASH in human subjects. These data highlight the potential usefulness of this test as a noninvasive diagnostic means of determining histological disease severity in patients with NAFLD. (HEPATOLOGY 2006;44:27–33.)

[1]  G. Gores,et al.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .

[2]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[3]  G. Gores,et al.  Apoptosis in alcoholic and nonalcoholic steatohepatitis. , 2005, Frontiers in bioscience : a journal and virtual library.

[4]  K. Batts,et al.  Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  A. Diehl,et al.  Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[6]  G. Gores,et al.  Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. , 2003, Journal of hepatology.

[7]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[8]  M. Manns,et al.  The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum , 2005, Hepatology.

[9]  H. Cortez‐Pinto,et al.  Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients , 2004, The American Journal of Gastroenterology.

[10]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[11]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[12]  G. Gores,et al.  Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic , 2003, Laboratory Investigation.

[13]  G. Gores,et al.  O0040 FREE FATTY ACIDS PROMOTE HEPATIC LIPOTOXICITY BY STIMULATING TNF‐ALPHA EXPRESSION VIA A LYSOSOMAL PATHWAY , 2004, Journal of Pediatric Gastroenterology and Nutrition.

[14]  G. Gores,et al.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.

[15]  J. Crespo,et al.  Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma , 2005, Obesity surgery.

[16]  H. Cortez‐Pinto,et al.  Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis , 2006, European journal of gastroenterology & hepatology.

[17]  K. Schulze-Osthoff,et al.  Detection of elevated caspase activation and early apoptosis in liver diseases. , 2001, European journal of cell biology.

[18]  G. Gores,et al.  Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.

[19]  A. Feldstein,et al.  Nonalcoholic fatty liver disease in the pediatric population: a review , 2005, Current opinion in pediatrics.

[20]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[21]  A. Sanyal,et al.  Evaluation and management of non-alcoholic steatohepatitis. , 2005, Journal of hepatology.

[22]  M. Manns,et al.  Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury , 2004, Hepatology.

[23]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[24]  G. Gores,et al.  Apoptosis: The nexus of liver injury and fibrosis , 2004, Hepatology.